Real-world data of pyrotinib-based therapy for patients with brain metastases of HER2-positive advanced breast cancer: a single-center retrospective analysis and molecular portraits

Real-world data of pyrotinib-based therapy for patients with brain metastases of HER2-positive advanced breast cancer: a single-center retrospective analysis and molecular portraits

IntroductionPyrotinib is a novel irreversible pan-HER tyrosine kinase inhibitor (TKI). However, real-world data of pyrotinib-containing therapy in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) and developing brain metastases (BMs) are limited, and the genomi...

Full description

Bibliographic Details
Main Authors: Hui Wang, Qiaoyan Liu, Mi Zhang, Juan Zhang, Ran Ran, Yingying Ma, Jiao Yang, Fan Wang, Shujuan He, Xiaoai Zhao, Le Wang, Lingxiao Zhang, Danfeng Dong, Jin Yang
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-06-01
Series:Frontiers in Oncology
Subjects:
HER2-positive breast cancer
brain metastases
pyrotinib
clinical benefits
genomic profile
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1105474/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1105474/full

Similar Items